MCL Literature Feed

Digital analysis of p53 immunohistochemistry establishes specific cut-offs (e.g., >50% for 2+/3+ nuclei) that reliably identify TP53 mutations and predict worse survival, improving rapid risk stratification.

This review summarizes the integration of BTK inhibitors into frontline MCL therapy and the emerging role of MRD, providing a treatment algorithm for managing newly diagnosed patients.

A rare case of composite CLL/MCL highlights diagnostic challenges from overlapping immunophenotypes, reinforcing the critical need for molecular and cytogenetic studies like FISH for t(11;14) for definitive diagnosis.

This case report of an 80-year-old man with MCL presenting with severe hyperleukocytosis (>491x10^9/L) highlights the diagnostic challenge of differentiating this rare presentation from other leukemias.

In elderly, frontline MCL, this SHINE secondary analysis shows achieving a complete response is critical for long-term PFS, and adding ibrutinib to BR significantly increases CR rates.

This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.

Retrospective data show B symptoms and CBV conditioning negatively impact survival post-ASCT in MCL, supporting BeEAM conditioning and risk-adapted strategies for consolidation.

This case report highlights the risk of life-threatening invasive aspergillosis in an elderly MCL patient with chronic neutropenia, underscoring the need for high clinical suspicion for fungal infections.

This phase II trial protocol compares chemo-free ibrutinib/venetoclax/rituximab versus ibrutinib-chemoimmunotherapy in treatment-naive elderly MCL, aiming to establish a new frontline standard.

Serum beta-2 microglobulin is a critical prognostic biomarker in lymphoma, including MCL, where it reflects tumor burden and is a key component of the MIPI risk score.

This case series reports fatal Hepatitis B reactivation with ibrutinib and breakthrough reactivation on zanubrutinib despite prophylaxis, highlighting the need for vigilant HBV monitoring with all BTKis.

This case report describes a rare intrasinusoidal presentation of pleomorphic MCL, highlighting a critical diagnostic pitfall that can mimic intravascular large B-cell lymphoma.

Korean real-world data confirms consolidative auto-SCT is effective, while in the relapsed setting, auto-SCT benefits chemosensitive patients and matched-donor allo-SCT is a viable option for refractory disease.

The t(11;14) translocation in MCL upregulates entire gene regulons across the chromosome arm via long-range chromatin interactions, revealing a novel mechanism of widespread oncogenic dysregulation beyond just CCND1.

A novel dual PI3K/HDAC inhibitor demonstrates enhanced pro-apoptotic activity in lymphoma cells, presenting a potential new preclinical strategy for MCL by simultaneously targeting two key pathways.

This case report demonstrates that secondary prostatic MCL can mimic prostate cancer, and transurethral resection can effectively manage resultant urinary retention, highlighting a rare extramedullary presentation.

This case report describes a rare presentation of mantle cell lymphoma with involvement of the entire gastrointestinal tract, highlighting diverse endoscopic findings beyond typical nodular or polypoid lesions.

This review characterizes the rare transformation of MCL into aggressive Burkitt lymphoma, a distinct form of Richter's syndrome, highlighting its unique pathogenesis, clinical features, and poor prognosis.

A preclinical mouse study reveals acalabrutinib alleviates fatty liver disease by regulating bile acid metabolism, suggesting a novel, off-target effect potentially beneficial for MCL patients with this comorbidity.

High NSD2 expression and specific mutations correlate with aggressive MCL variants, poorer treatment response, and inferior survival, establishing NSD2 as a key prognostic biomarker and potential therapeutic target.

Genomic analysis of MCL treated sequentially with BTKi and venetoclax identifies specific copy number alterations (e.g., 9p21.3 deletion) as novel biomarkers for primary and acquired resistance.

A commentary on a 40-year retrospective analysis confirms that therapeutic advances have led to gradual but significant improvements in overall survival for mantle cell lymphoma patients.

This review of CAR-T for MCL highlights the critical need for structured collaboration between specialized centers and community practices to manage toxicities and ensure successful patient outcomes.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

The Endothelial Activation and Stress Index (EASIX) is a novel, independent prognostic biomarker in MCL, with high scores at diagnosis correlating with significantly shorter OS and PFS.

The SOX11:SMARCA4 complex is a key oncogenic driver in MCL, and targeting SMARCA4 with a PROTAC degrader shows preclinical activity, offering a novel therapeutic strategy for relapsed patients.

Preclinical data show CBX5 loss drives PI3Kδ inhibitor resistance in MCL, which is reversed by propolis-derived CAPE via induction of CBX5-mediated ferroptosis, a novel therapeutic strategy.

A novel para-phenylenediamine-based ROR1 inhibitor demonstrates potent preclinical activity against an MCL cell line (JeKo-1), establishing a new chemical scaffold for targeting this promising therapeutic pathway.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

Dual-targeting CD20/CD19 CAR-T cells, using an adaptive on-site manufacturing process, achieved a 100% overall response rate with a favorable safety profile in relapsed/refractory MCL.